Voloridge Investment Management
STOK icon

Voloridge Investment Management’s Stoke Therapeutics STOK Stock Holding History

Voloridge Investment Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-86,888
Closed -$958K – 1359
2024
Q4 		$958K Sell
86,888
-36,261
-29% -$445K ﹤0.01% 1040
2024
Q3 		$1.51M Sell
123,149
-75,131
-38% -$1.06M 0.01% 976
2024
Q2 		$2.68M Buy
+198,280
New +$2.68M 0.01% 898
2021
Q4 		– Sell
-8,191
Closed -$208K – 1835
2021
Q3 		$208K Sell
8,191
-21,552
-72% -$601K ﹤0.01% 1583
2021
Q2 		$1M Buy
29,743
+21,474
+260% +$759K 0.01% 1253
2021
Q1 		$321K Buy
+8,269
New +$471K ﹤0.01% 1256

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Voloridge Investment Management's STOK Position: Q1 2025 in Review

Voloridge Investment Management sold out of Stoke Therapeutics (STOK) in Q1 2025, closing a stake of 86,888 shares — an estimated $958K sold.

Voloridge Investment Management first reported a position in STOK in Q1 2021 and held it in 6 quarters. The position peaked at $2.68M in Q2 2024. 126 funds tracked by Wall St. Rank hold STOK as of Q1 2025.

  • Voloridge Investment Management reported no remaining Stoke Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Voloridge Investment Management sold 86,888 Stoke Therapeutics shares in Q1 2025, an estimated $958K.
  • Voloridge Investment Management first reported a position in Stoke Therapeutics in Q1 2021 and held it in 6 quarters.
  • Voloridge Investment Management's Stoke Therapeutics position peaked at $2.68M in Q2 2024.
  • 126 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2025.

Based on Voloridge Investment Management's 13F filing for Q1 2025, filed 15 May 2025.